My Nightingale’s blood-based health tracking service provides indicators that are not usually available such as inflammation. Credit: Belova59 from Pixabay.

Finland-based blood testing technology provider Nightingale Health has opened a private placement round of €50m-€80m as part of its strategy to take its preventative health technology to international markets.

Carnegie is the advisor for the private placement round.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Meanwhile, the company also launched My Nightingale’s blood-testing service to deliver preventative healthcare.

Nightingale Health has received regulatory approval in Europe for its My Nightingale service.

Nightingale Health founder and chief executive officer Teemu Suna said: “We are honoured to have strong strategic partners in Japan and the US, who are not only investors in Nightingale but also business partners who are helping us take our technology to major markets.

“To make this launch as big as it deserves to be, we are raising, with the help of Carnegie, €50m-€80m in a new round of funding.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

My Nightingale provides indicators not routinely available such as inflammation, omega-3 and omega-6 fatty acids and insulin sensitivity, with predictions of a disease up to ten years in advance.

Suna said: “We are giving individuals access to health information that was previously available only for scientists. That’s because our aim is to equip people with the best tools that can help them increase their health spans and live healthy lives.”

Patients can access their blood test results via My Nightingale app, which provides the results in an easy-to-understand style.

This service is currently available in Helsinki and will soon be accessible at Nightingale Nest locations in international markets.

Suna said: “Launching the consumer service and starting the international roll-out of Nightingale’s technology is only the first step in our journey. In the coming years, we aim to expand rapidly and make Nightingale’s technology available all over the world, both to grow our business and help everyone live a healthier life.”